SA Anabolic. TIRZEP (Tirzepatide 10 mg/vial)

Tirzepatide – Key Properties - Type: Dual agonist (GLP-1 and GIP receptors) - Indication: -- Type 2 diabetes (FDA-approved as Mounjaro) -- Obesity/weight management (FDA-approved as Zepbound) - Mechanism: -- GLP-1 → appetite suppression, delayed gastric emptying, improved blood sugar control -- GIP → enhances insulin secretion, supports metabolic balance, may increase weight loss effects - Effectiveness (clinical data): -- Average weight loss up to 20–22% of body weight (in non-diabetic obese adults, depending on dose and duration) -- Improves HbA1c and insulin sensitivity in type 2 diabetes - Side effects: -- Nausea, vomiting, diarrhea, constipation, GI discomfort -- Possible risk of gallbladder issues, pancreatitis (similar to GLP-1 drugs) - Status: -- Approved for both diabetes and obesity treatment (as of 2025)